The major goal of this project is to understand how the nature of the carrier ligand affects resistance platinum drugs. In particular, we are interested in carrier ligand effects involving diaminocyclohexane (dach)-Pt compounds, since one of these compounds, ormaplatin (OP), is currently in clinical trial. Our data show no significant carrier ligand effects on bulk DNA repair of Pt adducts in the L1210 cell lines, but do not eliminate the possibility of carrier ligand effects on gene specific repair. Thus, we propose to collaborate with Dr. Vilhelm Bohr to determine whether there are any carrier ligand effects on gene specific repair in the L1210 cell lines. We have characterized carrier ligand effects in some detail with the human cell lines, but have not completely resolved the issue of which of these carrier ligand effects are most predictive dach-Pt sensitivity in cisplatin (CP)-resistant tumors. Thus, we plan to: (a) compare carrier ligand effects uptake and efflux, tolerance of PT-DNA adducts, repair and bypass replication for A2780/DDP, which shows no carrier ligand effects on resistance, and A2780/CP8, another CP-resistant derivative of A2780 which retains sensitivity to dach-Pt compounds; (b) confirm carrier ligand effects on repair by an independent assay; and (c) determine carrier ligand effects on bypass replication. Recent studies have suggested that decreased accumulation of platinum may be an important mechanism of resistance in many 11 lines. Unfortunately, the mechanism of platinum accumulation is not known in detail, in part because of the lack of suitable radiolabeled platinum compounds and in part because of the difficulty in separating efflux from the metabolism of platinum complexes. Our data show that the pattern of uptake OP and CP is essentially the same in the human cell lines we are studying. Thus, we plan to: (a) use the 3H- OP we have prepared previously to characterize uptake and efflux in detail; (b) use the HPLC techniques we have devised to determine the effects of intracellular metabolism on uptake and efflux; and prepare a non-metabolizable platinum complex for uptake and efflux studies. Finally, our data suggest at both repair and bypass replication may be inducible. Thus, we plan to: (a) determine the extent to which both repair and bypass replication are inducible, whether the induction of those processes is required for the resistant phenotype, and whether carrier ligand effects are expressed at the level of induction; (b) use the transient chloramphenical acetyltransferase expression assay to characterize the induction of gene expression in our cell lines; and (c) determine if the signal for the induction of gene expression is Pt damage on DNA. By identifying the sites and mechanisms of carrier ligand effects on resistance, it is hoped that is research will: (1) lead to improved strategies (eg combination chemotherapy) for overcoming resistance with dach-Pt compounds; (2) help identify the tumor types most likely to respond to dach-Pt drugs; and (3) lead to the design of even more effective platinum compounds.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA034082-07A2
Application #
3171823
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1987-02-01
Project End
1994-11-30
Budget Start
1991-12-15
Budget End
1992-11-30
Support Year
7
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
Schools of Medicine
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Vaisman, A; Varchenko, M; Umar, A et al. (1998) The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 58:3579-85
Vaisman, A; Varchenko, M; Said, I et al. (1997) Cell cycle changes associated with formation of Pt-DNA adducts in human ovarian carcinoma cells with different cisplatin sensitivity. Cytometry 27:54-64
Delmastro, D A; Li, J; Vaisman, A et al. (1997) DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 39:245-53
Chaney, S G; Sancar, A (1996) DNA repair: enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst 88:1346-60
Vaisman, A; Keeney, S; Nichols, A F et al. (1996) Cisplatin-induced alterations in the expression of the mRNAs for UV-damage recognition protein. Oncol Res 8:7-12
Petersen, L N; Mamenta, E L; Stevnsner, T et al. (1996) Increased gene specific repair of cisplatin induced interstrand crosslinks in cisplatin resistant cell lines, and studies on carrier ligand specificity. Carcinogenesis 17:2597-602
Vaisman, A; Chaney, S G (1995) Induction of UV-damage recognition protein by cisplatin treatment. Biochemistry 34:105-14
Mamenta, E L; Poma, E E; Kaufmann, W K et al. (1994) Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 54:3500-5
Schmidt, W; Chaney, S G (1993) Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Res 53:799-805
Nichols, A F; Schmidt, W J; Chaney, S G et al. (1992) Limitations of the in vitro repair synthesis assay for probing the role of DNA repair in platinum resistance. Chem Biol Interact 81:223-31

Showing the most recent 10 out of 24 publications